I know @Davisite says we're more advanced than what some media states, but having a look at the full program, I believe clarity is still earlier than its peers.
255ac is in the main prostate cancer speaking program, whilst clarity is speaking in a program where they're still discussing the viability of cu64/67.
I believe this shows why moves were made for other radioconjugates, and we're still moving forward. I hope this stays the case until we at least release our P1/2 data. P1 255ac has been out for years, whereas clarity hasn't formally released and Journal articles about their cu67, as it's still in progress.
I know @Davisite says we're more advanced than what some media...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.94 |
Change
-0.030(0.76%) |
Mkt cap ! $1.224B | |||
| Open | High | Low | Value | Volume |
| $4.01 | $4.06 | $3.93 | $3.866M | 966.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 13500 | $3.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.97 | 880 | 3 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$3.94 |
Change
-0.030 ( 1.22 %) |
||||
| Open | High | Low | Volume | ||
| $4.04 | $4.05 | $3.93 | 176194 | ||
| Last updated 15.59pm 14/05/2024 ? | |||||
| CU6 (ASX) Chart |